NASH/NAFLD and The Management of Abnormal Liver Function Tests
17 Nov 2022
Heart and Kidney Clinic
This session aims to bridge the gap between hepatology and metabolic disease, targeting NAFLD/NASH burden in Type 2 Diabetes.
It will highlight the new treatment paradigm of cardiometabolic disease and the subsequent interplay between non-alcoholic liver disease, obesity and Type 2 Diabetes.
This session will give an overview of current and ongoing research in this area and the potential of newer therapies (e.g. GLP1 receptor agonists and SGLT2 inhibitors) for preventing and treating NAFLD/NASH.
An unmissable session for anyone whose interest goes beyond the pancreas!
- To highlight the correlation between NAFLD/NASH, obesity and Type 2 Diabetes.
- To discuss the interplay of NAFLD/NASH, obesity and Type 2 Diabetes as cardiometabolic risk factors.
- To review the management of NAFLD/NASH in the presence of Type 2 Diabetes.
- To review key evidence (published and ongoing studies) in this area.
